ClinicalTrials.gg
Not yet recruitingNCT03271632Updated Oct 30, 2026

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

A Phase 1/2 interventional study of CAR T cells in Multiple Myeloma, sponsored by Shenzhen Geno-Immune Medical Institute. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Shenzhen Geno-Immune Medical Institute · Phase 1/2, Interventional, and Treatment

Updated Oct 30, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Planned enrollment
273rd of 406
20 · median 40
Started
2026
with 53 others
Phase 1/2
65 of 448
43 open now
Primary completion
2029-12
later than 256 of 274 live
Registered
46th of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 273rd largest by planned enrollment of the 406 interventional ones that give a count, is one of 54 that started in 2026, is one of 65 in phase 1/2, reaches primary completion later than 256 of the 274 other live ones, and was the 46th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

233 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

The aim of this clinical trial is to assess the feasibility, safety and efficacy of autologous CAR T cell immunotherapy targeting multiple cancer cell surface antigens in relapsed and refractory multiple myeloma patients. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.

Read the detailed description

Important Regulatory Notice:

This trial record is only for global academic information registration on ClinicalTrials.gov. Neither the sponsor Beijing Meikang Jimian Biotechnology Co., Ltd. nor collaborator Shenzhen Geno-Immune Medical Institute has obtained NMPA clinical trial approval or clinical technology filing permission to carry out interventional cell therapy trials in mainland China.

ClinicalTrials.gov registration alone does not represent legal approval by Chinese health and drug regulatory authorities.

Multiple myeloma (MM) is a malignancy of plasma cells, which remains a clinical challenge despite advanced therapeutic interventions including novel molecular therapies and stem cell transplantation (SCT). This trial is to test the safety and efficacy of T cells genetically modified to specifically target several MM surface antigens, including BCMA, CD38, CD56, CD138 or alternative MM surface antigens, based on a multi-CAR T cell immunotherapy approach. Another goal of the study is to investigate the persistence and function of CAR T cells in the body after CAR T cell infusion.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • multiple myeloma
  • chimeric antigen receptor
  • BCMA
  • CD38
  • CD56
  • CD138
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects with surface antigen confirmed multiple myeloma with no available curative treatment options (including or allogeneic SCT).
  • Complete remission (CR) cannot be achieved after at least 4 prior combination therapy regimens.
  • MM in CR2 or CR3 and not eligible for allogeneic SCT because of age, comorbid diseases, or lack of available donor.
  • Less than 1 year between last chemotherapy and progression (i.e. most recent progression free interval \< 1 year).
  • after prior autologous or allogenic SCT MM patients with relapsed or residual disease after at least 1 prior therapy and not eligible for allogeneic SCT.
  • Residual disease after primary therapy and not eligible for ASCT
  • Expected survival > 12 weeks
  • Creatinine \< 2.5 mg/dl
  • (alanine aminotransferase)/AST (aspartate aminotransferase) \< 3x normal
  • \< 2.0 mg/dl
  • Any relapse after prior SCT is eligible regardless of other prior therapy
  • Adequate venous access for apheresis, and no other for leukapheresis
  • Voluntary is given

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women
  • Uncontrolled active infection
  • Active or infection
  • Concurrent use of systemic . Recent or current use of inhaled steroids is not exclusionary.
  • Previous related CAR-T cell therapy Any uncontrolled active medical disorder that would preclude participation
  • infection
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Single arm

    CAR T cells to treat MM

    Biological: CAR T cells

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of patients with treatment related adverse effect

    percentage of participants with treatment-related adverse events, as assessed by physical exam, vital signs, standard clinical lab tests.

    Time frame: 1 month

Secondary outcomes

  1. Anti-tumor activity of fourth generation multiple CAR-T cells after infusion

    by measuring CAR copies in the body

    Time frame: 1 year

  2. Anti-tumor activity of fourth generation multiple CAR-T cells in patients with relapsed or refractory MM

    by physical examination of tumor burden

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.

Of 103 non-industry phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 94. This study's planned 36 months is below that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2017
First posted
Sep 5, 2017
StartEst.
Dec 31, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2030
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact's phone or email changed: c•••@szgimi.org→c•••@mkgimi.com. See the current contact
Oct 30, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Shenzhen Geno-immune Medical Institute · Shenzhen, ChinaContact c•••@szgimi.org→c•••@mkgimi.com
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Contact Study contact's phone or email changed: c•••@szgimi.org→c•••@mkgimi.com. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Shenzhen Geno-immune Medical Institute · Shenzhen, ChinaContact c•••@szgimi.org→c•••@mkgimi.com
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03271632
Lead sponsor
Shenzhen Geno-Immune Medical Institute
Responsible party
Lung-Ji Chang (Principal Investigator, Shenzhen Geno-Immune Medical Institute) — Principal investigator
First posted
Sep 5, 2017
Start date
Dec 31, 2026 (estimated)
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Oct 30, 2026

Study contacts

Lung-Ji Chang
Contact
c@mkgimi.com
+86 0755-86573763
Lung-Ji Chang
principal investigator · Shenzhen Geno-Immune Medical Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chimeric Antigen Receptor T-cells

Start the discussion